Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

MicroRNAs as theranostic markers in cardiac allograft transplantation: from murine models to clinical practice

J. Novák, T. Macháčková, J. Krejčí, J. Bienertová-Vašků, O. Slabý

. 2021 ; 11 (12) : 6058-6073. [pub] 20210407

Jazyk angličtina Země Austrálie

Typ dokumentu časopisecké články, práce podpořená grantem, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc21025865

Grantová podpora
NV16-30537A MZ0 CEP - Centrální evidence projektů

Congestive heart failure affects about 23 million people worldwide, and cardiac allograft transplantation remains one of the last options for patients with terminal refractory heart failure. Besides the infectious or oncological complications, the prognosis of patients after heart transplantation is affected by acute cellular or antibody-mediated rejection and allograft vasculopathy development. Current monitoring of both conditions requires the performance of invasive procedures (endomyocardial biopsy sampling and coronary angiography or optical coherence tomography, respectively) that are costly, time-demanding, and non-comfortable for the patient. Within this narrative review, we focus on the potential pathophysiological and clinical roles of microRNAs (miRNAs, miRs) in the field of cardiac allograft transplantation. Firstly, we provide a general introduction about the status of cardiac allograft function monitoring and the discovery of miRNAs as post-transcriptional regulators of gene expression and clinically relevant biomarkers found in the extracellular fluid. After this general introduction, information from animal and human studies are summarized to underline the importance of miRNAs both in the pathophysiology of the rejection process, the possibility of its modulation by altering miRNAs levels, and last but not least, about the use of miRNAs in the clinical practice to diagnose or predict the rejection occurrence.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21025865
003      
CZ-PrNML
005      
20211026133432.0
007      
ta
008      
211013s2021 at f 000 0|eng||
009      
AR
024    7_
$a 10.7150/thno.56327 $2 doi
035    __
$a (PubMed)33897899
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a at
100    1_
$a Novák, Jan $u Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Kamenice 5-A18, 625 00, Brno, Czech Republic $u Second Department of Internal Medicine, St. Anne's University Hospital and Faculty of Medicine, Masaryk University, Pekařská 53, 65691, Brno, Czech Republic $u Central European Institute of Technology, Masaryk University, Kamenice 5-A35, 625 00, Brno, Czech Republic
245    10
$a MicroRNAs as theranostic markers in cardiac allograft transplantation: from murine models to clinical practice / $c J. Novák, T. Macháčková, J. Krejčí, J. Bienertová-Vašků, O. Slabý
520    9_
$a Congestive heart failure affects about 23 million people worldwide, and cardiac allograft transplantation remains one of the last options for patients with terminal refractory heart failure. Besides the infectious or oncological complications, the prognosis of patients after heart transplantation is affected by acute cellular or antibody-mediated rejection and allograft vasculopathy development. Current monitoring of both conditions requires the performance of invasive procedures (endomyocardial biopsy sampling and coronary angiography or optical coherence tomography, respectively) that are costly, time-demanding, and non-comfortable for the patient. Within this narrative review, we focus on the potential pathophysiological and clinical roles of microRNAs (miRNAs, miRs) in the field of cardiac allograft transplantation. Firstly, we provide a general introduction about the status of cardiac allograft function monitoring and the discovery of miRNAs as post-transcriptional regulators of gene expression and clinically relevant biomarkers found in the extracellular fluid. After this general introduction, information from animal and human studies are summarized to underline the importance of miRNAs both in the pathophysiology of the rejection process, the possibility of its modulation by altering miRNAs levels, and last but not least, about the use of miRNAs in the clinical practice to diagnose or predict the rejection occurrence.
650    _2
$a alografty $x metabolismus $7 D064591
650    _2
$a zvířata $7 D000818
650    _2
$a biologické markery $x metabolismus $7 D015415
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a transplantace srdce $x metody $7 D016027
650    _2
$a lidé $7 D006801
650    _2
$a mikro RNA $x metabolismus $7 D035683
650    _2
$a myokard $x metabolismus $7 D009206
650    _2
$a homologní transplantace $x metody $7 D014184
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Macháčková, Táňa $u Central European Institute of Technology, Masaryk University, Kamenice 5-A35, 625 00, Brno, Czech Republic
700    1_
$a Krejčí, Jan $u Department of Cardiovascular Diseases, St. Anne's University Hospital and Faculty of Medicine, Masaryk University, Pekařská 53, 65691, Brno, Czech Republic
700    1_
$a Bienertová-Vašků, Julie $u Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Kamenice 5-A18, 625 00, Brno, Czech Republic $u RECETOX, Faculty of Sciences, Masaryk University, Kamenice 5-A29, 625 00, Brno, Czech Republic
700    1_
$a Slabý, Ondřej $u Central European Institute of Technology, Masaryk University, Kamenice 5-A35, 625 00, Brno, Czech Republic $u Department of Biology, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic
773    0_
$w MED00177173 $t Theranostics $x 1838-7640 $g Roč. 11, č. 12 (2021), s. 6058-6073
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33897899 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026133438 $b ABA008
999    __
$a ok $b bmc $g 1714770 $s 1146372
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 11 $c 12 $d 6058-6073 $e 20210407 $i 1838-7640 $m Theranostics $n Theranostics $x MED00177173
GRA    __
$a NV16-30537A $p MZ0
LZP    __
$a Pubmed-20211013

Najít záznam

Citační ukazatele

Možnosti archivace